Journal of Pharmaceutical Microbiology

Alzheimer’s disease (AD) is considered the most devastating neurodegenerative disorder that affects more than 50 million people worldwide. AD

is a complex and multifactorial disease where endogenous and exogenous factors can be involved in the triggering of this illness, whose hallmark

is amyloid-β (Aβ), formed by cleavage of amyloid precursor protein by β- and γ-secretase. While there is no definitive cure for AD to date, drug

discovery based on nutraceutical molecules for prevention and treatment of AD is a growing topic. As well as helping to delay disease development,

natural products such as carotenoid and polyphenol compounds have demonstrated positive preventive efficacy.. We are focus on carotenoids

by their chemical structure and their neuroprotective activity against Aβ aggregation using molecular docking analysis. In our computational

analysis, lutein showed the most prevalent anti-amyloidogenic followed by cryptocapsin, astaxanthin, fucoxanthin, and the apocarotenoid bixin

where important interactions between carotenoids and Aβ via hydrogen bonding and van der Waals interactions were involved. Curcumin is

another interesting natural product that revealed to be a potential compound for treating of AD following different neuroprotective mechanisms,

such as inhibition of aggregation and decrease in brain inflammation. But, the low bioavailability, and susceptibility to degradation in biological

systems and poor solubility in plasma avoid converting this compound a medicine, but curcumin derivatives can be a potential alternative. We

synthesised new derivatives of curcumin in order to have strong anti-aggregation ability but also enhanced anti-inflammatory behaviour. One

curcumin derivatives exhibited a strong anti-aggregation effect higher than curcumin. Better bioactivity than difunctionalized compounds was

demonstrated by monofunctionalized curcumin derivatives. Analysis of molecular docking showed that carotenoids and curcumin derivatives

might adopt two pathways to inhibit Aβ aggregation: one by preventing fibril formation and the second by disruption Our studies thus illuminate

mechanistic insights on how carotenoids and curcumin derivatives can inhibit Aβ aggregation.